Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Bladder Cancer

Free Subscription 15.05.2023 1 Aging (Albany NY) 1 Aging Male 2 Altern Ther Health Med 2 Am J Clin Exp Urol 1 Ann Surg Oncol 3 BMC Urol 1 Cancer Cell 1 Cancer Cell Int 1 Cancer Med 1 Cell Oncol (Dordr) 1 Clin Transl Med 1 Eur Urol Focus 1 Front Endocrinol (Lausanne) 2 Front Immunol 1 Front Oncol 1 Front Pharmacol 1 Int J Cancer 1 Int J Health Sci (Qassim) 1 Int J Urol 1 J Cancer Res Clin Oncol 1 J Cancer Res Ther 2 J Urol 1 JBI Evid Implement 1 Math Biosci Eng 1 Medicine (Baltimore) 1 Mol Carcinog 1 Oncol Rep 1 Orphanet J Rare Dis 1 Pathol Oncol Res 1 Sci Rep 1 Small 1 Urol Oncol 1 Urologie 1 Vascular 4 World J Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aging (Albany NY)

1. HSIEH TY, Sung WW, Chang YC, Yu CY, et al
   Melatonin induces cell cycle arrest and suppresses tumor invasion in urinary bladder urothelial carcinoma.
   Aging (Albany NY). 2023;15:3107-3119.
   PubMed         Abstract available
   
   

   
   Aging Male

2. TIAN G, Li Y, Nie L, Liu S, et al
   Cervical lymph node metastasis of bladder cancer: a case report and review of literature.
   Aging Male. 2023;26:2205935.
   PubMed         Abstract available
   
   

   
   Altern Ther Health Med

3. DAVIS D, Seely D, Morash C, Armstrong J, et al
   Complete Remission of BCG-Refractory High-grade Bladder CIS with Pharmacologic Ascorbate and Mistletoe.
   Altern Ther Health Med. 2023;29:6-17.
   PubMed         Abstract available
   
   
4. HINDERBERGER P, Winters N
   Mistletoe for Bladder Cancer: Call for More Case Reports Using the Intravesical Route.
   Altern Ther Health Med. 2023;29:18-19.
   PubMed         Abstract available
   
   

   
   Am J Clin Exp Urol

5. KENNELLEY GE, Amaye-Obu T, Foster BA, Tang L, et al
   Mechanistic review of sulforaphane as a chemoprotective agent in bladder cancer.
   Am J Clin Exp Urol. 2023;11:103-120.
   PubMed         Abstract available
   
   
6. BAZARGANI S, Lall C, Gopireddy DR, Liu S, et al
   Extramural venous invasion: a novel magnetic resonance imaging biomarker for adverse pathology in bladder cancer.
   Am J Clin Exp Urol. 2023;11:185-193.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

7. YU J, Lee J, Ha S, Baek JW, et al
   Impact of Chart-Derived Frailty Index on 1-Year Mortality After Radical Cystectomy in 1004 Patients with Bladder Cancer.
   Ann Surg Oncol. 2023 May 9. doi: 10.1245/s10434-023-13565.
   PubMed         Abstract available
   
   

   
   BMC Urol

8. SEILER R, Egger M, De Menna M, Wehrli S, et al
   Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial.
   BMC Urol. 2023;23:89.
   PubMed         Abstract available
   
   
9. ZHANG B, Liu T, He Y, Han D, et al
   Clinical application and efficacy analysis of partial cystectomy combined with intravesical chemotherapy in muscle-invasive bladder cancer.
   BMC Urol. 2023;23:91.
   PubMed         Abstract available
   
   
10. OHTSU A, Arai S, Fujizuka Y, Fukuda R, et al
    Retroperitoneal urothelial carcinoma arising after bladder diverticulectomy: a case report.
    BMC Urol. 2023;23:88.
    PubMed         Abstract available
    
    

    
    Cancer Cell

11. JANA S, Brahma S, Arora S, Wladyka CL, et al
    Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression.
    Cancer Cell. 2023;41:853-870.
    PubMed         Abstract available
    
    

    
    Cancer Cell Int

12. REN L, Yang X, Liu J, Wang W, et al
    An innovative model based on N7-methylguanosine-related lncRNAs for forecasting prognosis and tumor immune landscape in bladder cancer.
    Cancer Cell Int. 2023;23:85.
    PubMed         Abstract available
    
    

    
    Cancer Med

13. KE C, Hu Z, Yang C
    Preoperative accuracy of diagnostic evaluation of urachal carcinoma.
    Cancer Med. 2023;12:9106-9115.
    PubMed         Abstract available
    
    

    
    Cell Oncol (Dordr)

14. ZHENG Y, Wang X, Yang X, Xing N, et al
    Single-cell RNA sequencing reveals the cellular and molecular characteristics of high-grade and metastatic bladder cancer.
    Cell Oncol (Dordr). 2023 May 11. doi: 10.1007/s13402-023-00820.
    PubMed         Abstract available
    
    

    
    Clin Transl Med

15. MOU Z, Chen Y, Zhang Z, Chen X, et al
    Cryoablation inhibits the recurrence and progression of bladder cancer by enhancing tumour-specific immunity.
    Clin Transl Med. 2023;13:e1255.
    PubMed         Abstract available
    
    

    
    Eur Urol Focus

16. NURMINEN P, Nummi A, Kesti O, Ettala O, et al
    Comparison of Bacillus Calmette-Guerin Maintenance Therapy with Monthly Instillations and the Southwest Oncology Group Protocol in the Treatment of Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2023 May 9:S2405-4569(23)00110-4. doi: 10.1016/j.euf.2023.
    PubMed         Abstract available
    
    

    
    Front Endocrinol (Lausanne)

17. ZHAO S, Wang L, Ding W, Ye B, et al
    Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
    Front Endocrinol (Lausanne). 2023;14:1180404.
    PubMed         Abstract available
    
    

    
    Front Immunol

18. SHEN J, Hou H, Liang B, Guo X, et al
    Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Front Immunol. 2023;14:1155104.
    PubMed         Abstract available
    
    
19. DU Y, Liu Y, Cao J, Jiang X, et al
    LDL receptor related protein 1 is an adverse prognostic biomarker that correlates with stromal remodeling and macrophages infiltration in bladder cancer.
    Front Immunol. 2023;14:1113756.
    PubMed         Abstract available
    
    

    
    Front Oncol

20. ZHANG S, Li L, Yu P, Wu C, et al
    A deep learning model for drug screening and evaluation in bladder cancer organoids.
    Front Oncol. 2023;13:1064548.
    PubMed         Abstract available
    
    

    
    Front Pharmacol

21. ABUGOMAA A, Elbadawy M, Ishihara Y, Yamamoto H, et al
    Anti-cancer activity of Chaga mushroom (Inonotus obliquus) against dog bladder cancer organoids.
    Front Pharmacol. 2023;14:1159516.
    PubMed         Abstract available
    
    

    
    Int J Cancer

22. HOSSEINI B, Zendehdel K, Bouaoun L, Hall AL, et al
    Bladder cancer risk in relation to occupations held in a nationwide case-control study in Iran.
    Int J Cancer. 2023 May 9. doi: 10.1002/ijc.34560.
    PubMed         Abstract available
    
    

    
    Int J Health Sci (Qassim)

23. ANWAR M, Ejaz M, Ijaz M, Ahmad G, et al
    Association of IL-17A promoter region SNP-rs2275913 with urinary bladder cancer.
    Int J Health Sci (Qassim). 2023;17:33-38.
    PubMed         Abstract available
    
    

    
    Int J Urol

24. LIU Z, Leow JJ, Yong DZP
    Editorial Comment to Significance of dorsal bladder neck involvement in predicting the progression of non-muscle-invasive bladder cancer.
    Int J Urol. 2023 May 10. doi: 10.1111/iju.15200.
    PubMed        
    
    

    
    J Cancer Res Clin Oncol

25. WANG L, Huang S, Zhang P, Li H, et al
    The application of gemcitabine and pirarubicin in patients with non-muscle invasive bladder cancer.
    J Cancer Res Clin Oncol. 2023 May 9. doi: 10.1007/s00432-023-04739.
    PubMed         Abstract available
    
    

    
    J Cancer Res Ther

26. NAIK M, Rao BV, Challa S, Fonseca D, et al
    Utility of GATA-3 and associated immunohistochemical markers in the differential diagnosis of poorly differentiated urothelial carcinoma.
    J Cancer Res Ther. 2023;19.
    PubMed         Abstract available
    
    

    
    J Urol

27. WANG HH, Zhang TR, Ramakrishnan VM, Valovska MT, et al
    Long-term Urological Outcomes in Pelvic Genitourinary Rhabdomyosarcoma: A 48-Year Single-center Experience.
    J Urol. 2023;209:1202-1209.
    PubMed         Abstract available
    
    
28. COLEMAN JA, Clark PE, Bixler BR, Buckley DI, et al
    Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline.
    J Urol. 2023;209:1071-1081.
    PubMed         Abstract available
    
    

    
    JBI Evid Implement

29. HAJEBRAHIMI S, Talebpour A, Kabiri N, Ahmadian N, et al
    Promoting post-discharge telephone follow-up of patients with transurethral resection for bladder cancer: a best practice implementation project.
    JBI Evid Implement. 2023 May 10. doi: 10.1097/XEB.0000000000000374.
    PubMed         Abstract available
    
    

    
    Math Biosci Eng

30. JIANG T, Jin P, Huang G, Li SC, et al
    The function of guanylate binding protein 3 (GBP3) in human cancers by pan-cancer bioinformatics.
    Math Biosci Eng. 2023;20:9511-9529.
    PubMed         Abstract available
    
    

    
    Medicine (Baltimore)

31. TANG YC, Yang CS, Liang MX, Zhang Y, et al
    Development and evaluation of an adenosine-to-inosine RNA editing-based prognostic model for survival prediction of bladder cancer patients.
    Medicine (Baltimore). 2023;102:e33719.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

32. LUO Y, Zhang Y, Pang S, Min J, et al
    PCBP1 protects bladder cancer cells from mitochondria injury and ferroptosis by inducing LACTB mRNA degradation.
    Mol Carcinog. 2023 May 8. doi: 10.1002/mc.23533.
    PubMed         Abstract available
    
    

    
    Oncol Rep

33. HO JN, Jeon JS, Kim DH, Ryu H, et al
    CUDC‑907 suppresses epithelial‑mesenchymal transition, migration and invasion in a 3D spheroid model of bladder cancer.
    Oncol Rep. 2023;49:130.
    PubMed         Abstract available
    
    

    
    Orphanet J Rare Dis

34. WANG H, Gao Y, Qin L, Zhang M, et al
    Identification of a novel de novo mutation of SETBP1 and new findings of SETBP1 in tumorgenesis.
    Orphanet J Rare Dis. 2023;18:107.
    PubMed         Abstract available
    
    

    
    Pathol Oncol Res

35. REVESZ J, Posfai B, Pajor L, Papdan T, et al
    Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data.
    Pathol Oncol Res. 2023;29:1611077.
    PubMed         Abstract available
    
    

    
    Sci Rep

36. AHMAD U, Abdullah S, Chau M, Chia SL, et al
    Analysis of PPI networks of transcriptomic expression identifies hub genes associated with Newcastle disease virus persistent infection in bladder cancer.
    Sci Rep. 2023;13:7323.
    PubMed         Abstract available
    
    

    
    Small

37. DENG Y, Fu Y, Chua SL, Khoo BL, et al
    Biofilm Potentiates Cancer-Promoting Effects of Tumor-Associated Macrophages in a 3D Multi-Faceted Tumor Model.
    Small. 2023;19:e2205904.
    PubMed         Abstract available
    
    

    
    Urol Oncol

38. CZECH AK, Gronostaj K, Fronczek J, Frydrych J, et al
    Diagnostic accuracy of bimanual palpation in bladder cancer patients undergoing cystectomy: A prospective study.
    Urol Oncol. 2023 May 3:S1078-1439(23)00122-9. doi: 10.1016/j.urolonc.2023.
    PubMed         Abstract available
    
    

    
    Urologie

39. BOLENZ C, Zengerling F
    [Neoadjuvant chemotherapy in patients with high-risk upper tract urothelial carcinoma: current evidence].
    Urologie. 2023;62:522-524.
    PubMed        
    
    

    
    Vascular

40. LORENZO JF, Lopez Arquillo IM, Rey JV
    Primary aortoenteric fistula after intravesical instillation of Bacillus Calmette-Guerin for bladder cancer.
    Vascular. 2023 May 6:17085381231174923. doi: 10.1177/17085381231174923.
    PubMed         Abstract available
    
    

    
    World J Urol

41. ROUPRET M, Brouquet A, Colrat F, Diez-Andreu P, et al
    Population characteristics, management, and survival outcomes in muscle-invasive urothelial carcinoma undergoing radical resection: the MINOTAUR study.
    World J Urol. 2023;41:1069-1075.
    PubMed         Abstract available
    
    
42. VAN WIJNGAARDEN C, Bus MTJ, Ruiter AEC, Lagerveld BW, et al
    A 6-month maintenance schedule of mitomycin C after radical nephroureterectomy for upper tract urothelial carcinoma for the prevention of intravesical recurrence: a retrospective, single center study.
    World J Urol. 2023;41:1077-1083.
    PubMed         Abstract available
    
    
43. MORI K, Yanagisawa T, Katayama S, Laukhtina E, et al
    Impact of sex on outcomes after surgery for non-muscle-invasive and muscle-invasive bladder urothelial carcinoma: a systematic review and meta-analysis.
    World J Urol. 2023;41:909-919.
    PubMed         Abstract available
    
    
44. DICKMAN KG, Chen CH, Grollman AP, Pu YS, et al
    Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
    World J Urol. 2023;41:899-907.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: